GE HealthCare has established a licensing agreement to commercialize two fibroblast activated protein inhibitor (FAPI)-PET radiotracers developed by Sofie Biosciences for cancer imaging.
Under the agreement, GE HealthCare will take on global rights for gallium-68 (Ga-68) FAPI-46 and outside-U.S. rights for F-18 FAPI-74, originally developed at Heidelberg University in Germany. Sofie will continue its clinical development and commercialization program with F-18 FAPI-74 in the U.S., according to a release.
Both tracers are currently in phase II clinical trials in the U.S. The PET imaging radiotracers target cancer-associated fibroblasts, cells that are present in most tumor types, including breast, pancreatic, colorectal, lung, liver, and gastric, GE HealthCare said.
